| Name | Title | Contact Details |
|---|---|---|
Janne Kerovuo |
Chief Technology Officer | Profile |
Shawn Semones |
Chief Technology Officer | Profile |
Lumen Bioscience develops oral antibody therapeutics.
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.
Seattle Institute for Biomedical and Clinical Research is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.
BioTechniques is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.